Search

Your search keyword '"Javier Prieto"' showing total 42 results
Start Over Author "Javier Prieto" Topic medicine.disease
42 results on '"Javier Prieto"'

1. αKLOTHO and sTGFβR2 treatment counteract the osteoarthritic phenotype developed in a rat model

Author

Juan Manuel López-Alcorocho, Tomoaki Hishida, George M. Church, Chao Wang, Pedro Guillén-García, Yuriko Hishida, Isabel Guillén-Vicente, Elena Rodríguez-Iñigo, Reyna Hernández-Benítez, Akihisa Sakamoto, Concepcion Rodriguez Esteban, Fumiyuki Hatanaka, Marta Guillén-Vicente, Javier Prieto, Estrella Núñez-Delicado, Noah Davidsohn, Ling Huang, Paloma Martinez-Redondo, Kensaku Shojima, Pradeep Reddy, Masakazu Kurita, Juan Carlos Izpisua Belmonte, Amy N. Nemeth, Takashi Lezaki, Maxim N. Shokhirev, Cuiqing Zhong, Isabel Guillen-Guillen, Josep M. Campistol, and Guang-Hui Liu

Subjects
Cartilage, Articular, Letter, Cell Culture Techniques, lcsh:Animal biochemistry, Osteoarthritis, Biology, Biochemistry, Chondrocytes, Drug Discovery, Papain, medicine, Animals, Humans, lcsh:QH573-671, Receptor, Klotho Proteins, lcsh:QP501-801, Glucuronidase, lcsh:Cytology, Cartilage, Receptor, Transforming Growth Factor-beta Type II, Cell Biology, Osteoarthritis, Knee, medicine.disease, Phenotype, Human genetics, Recombinant Proteins, Cell biology, Rats, medicine.anatomical_structure, Cell culture, Stem cell, Developmental biology, Biotechnology
Published
2020

2. Parenteral Nutrition–Associated Hyperglycemia in Non–Critically Ill Inpatients Increases the Risk of In-Hospital Mortality (Multicenter Study)

Author

Anna Vila-Bundo, Lucio Cabrerizo, Mercedes Ferrer, Adela Rovira, Pilar García-Peris, Marta Diéguez, Francisco Botella-Romero, Javier Prieto, María C. Conde-García, María C. Tous, María D. Ballesteros-Pomar, Pedro Pujante, Irene Bretón, Juan Ramón Urgelés, Carmen Arraiza-Irigoyen, María J. Carrera, Araceli Muñoz-Garach, Álvaro García-Manzanares, Rosa Burgos, María José Tapia, J.L. Pereira, Carmen Aragón-Valera, Efren Márquez, Carmen Cabrejas-Gómez, Ana Zugasti, Julia Ocón, Dolores del Olmo, L. Chicharro, Pilar Matía, Rosa P. Quílez-Toboso, Gabriel Olveira, Josefina Olivares, and Alfonso Vidal-Casariego

Subjects
Male, Research design, medicine.medical_specialty, Critical Illness, Endocrinology, Diabetes and Metabolism, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Risk of mortality, Humans, Hospital Mortality, Prospective Studies, Prospective cohort study, Aged, Original Research, Advanced and Specialized Nursing, In hospital mortality, business.industry, Critically ill, Clinical Care/Education/Nutrition/Psychosocial Research, Middle Aged, medicine.disease, Surgery, Parenteral nutrition, Multicenter study, Hyperglycemia, Female, Parenteral Nutrition, Total, business
Abstract

OBJECTIVE Hyperglycemia may increase mortality in patients who receive total parenteral nutrition (TPN). However, this has not been well studied in noncritically ill patients (i.e., patients in the nonintensive care unit setting). The aim of this study was to determine whether mean blood glucose level during TPN infusion is associated with increased mortality in noncritically ill hospitalized patients. RESEARCH DESIGN AND METHODS This prospective multicenter study involved 19 Spanish hospitals. Noncritically ill patients who were prescribed TPN were included prospectively, and data were collected on demographic, clinical, and laboratory variables as well as on in-hospital mortality. RESULTS The study included 605 patients (mean age 63.2 ± 15.7 years). The daily mean TPN values were 1.630 ± 323 kcal, 3.2 ± 0.7 g carbohydrates/kg, 1.26 ± 0.3 g amino acids/kg, and 0.9 ± 0.2 g lipids/kg. Multiple logistic regression analysis showed that the patients who had mean blood glucose levels >180 mg/dL during the TPN infusion had a risk of mortality that was 5.6 times greater than those with mean blood glucose levels CONCLUSIONS Hyperglycemia (mean blood glucose level >180 mg/dL) in noncritically ill patients who receive TPN is associated with a higher risk of in-hospital mortality.

Published
2013

3. Development of novel epigenetic inhibitors for the treatment of hepatocellular carcinoma

Author

Matías A. Avila, Javier Prieto, Carmen Berasain, Marina Bárcena-Varela, Felipe Prosper, Maite G. Fernandez-Barrena, Jesus M. Banales, L. Alvarez-Asiain, and Julen Oyarzabal

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Hepatocellular carcinoma, medicine, Epigenetics, medicine.disease, business
Published
2017

4. Leukaemia of natural killer cell large granular lymphocyte type with HLA-DR-CD16-CD56bright+ phenotype

Author

Javier Prieto, J M de Blas, José Manuel Matilla Rodríguez, A. Parrado, E Ríos, and A. Martin

Subjects
Lymphocyte, CD38, CD16, Biology, Immunophenotyping, Pathology and Forensic Medicine, Natural killer cell, Fatal Outcome, hemic and lymphatic diseases, HLA-DR, medicine, Humans, Lymphokine-activated killer cell, General Medicine, Middle Aged, medicine.disease, Lymphocyte Subsets, Leukemia, Lymphoid, Killer Cells, Natural, Leukemia, medicine.anatomical_structure, Acute Disease, Immunology, Female, Research Article
Abstract

The case is reported of a 45 year old woman with the rare leukaemia of natural killer cell large granular lymphocyte (NK/ LGL) type. Cytometric analysis of leukaemic blasts showed that they were positive for CD2, CD38, and CD56 antigens but negative for a series of antigens including CD3, CD7, CD16, and HLA-DR. Rearrangements of the beta T cell receptor, and heavy and kappa immunoglobulin genes were not detected and neither were chromosomal abnormalities. Leukaemic blasts developed NK cytotoxicity. The patient failed to respond to aggressive chemotherapy and died three months after diagnosis. The lack of expression of HLA-DR is an extraordinary characteristic of this case, as all cases of acute NK cell leukaemias described to date expressed HLA-DR. The immunophenotype observed in the NK cell leukaemic blasts may represent the counterpart of a hypothetical normal cell precursor in an early stage of ontogenic NK cell development.

Published
1996

6. O138 PHASE 1 CLINICAL TRIAL OF LIVER DIRECTED GENE THERAPY WITH rAAV5-PBGD IN ACUTE INTERMITTENT PORPHYRIA: PRELIMINARY SAFETY DATA

Author

R. Enríquez de Salamanca, Javier Prieto, Gloria González-Aseguinolaza, A. Henrichson, R. Juan, María Eugenia Cornet, S. Abecia, Delia D'Avola, María del Mar Municio, A. Fontanellas, I. Troconiz, M. Paz, C. von Kalle, Manfred G. Schmidt, Pauline Harper, Florence Salmon, N. Grosios, Astrid Pañeda, Bruno Sangro, Esperanza Lopez-Franco, C. Fuertes, Christine Kaeppel, and Harald Petry

Subjects
medicine.medical_specialty, Hepatology, business.industry, Genetic enhancement, Internal medicine, Physical therapy, medicine, Phases of clinical research, medicine.disease, business, Acute intermittent porphyria
Published
2014

7. O72 PHASE 1–2 CLINICAL TRIAL IN PATIENTS WITH DECOMPENSATED LIVER CIRRHOSIS TREATED WITH BONE-MARROW DERIVED ENDOTHELIAL PROGENITOR CELLS: PRELIMINARY SAFETY AND EFFICACY ANALYSIS

Author

J.I. Herrero, Jorge Quiroga, J.I. Bilbao, C. Fuertes, Bruno Sangro, Felipe Prosper, Veronica Fernandez-Ruiz, Mercedes Iñarrairaegui, Enrique J. Andreu, Javier Prieto, M. Mendez, Delia D'Avola, and F. Carmona-Torre

Subjects
medicine.medical_specialty, Pathology, Cirrhosis, Hepatology, business.industry, medicine.disease, Gastroenterology, Clinical trial, medicine.anatomical_structure, Internal medicine, medicine, In patient, Bone marrow, Progenitor cell, business
Published
2014

8. O97 GUT-DERIVED FGF15 PLAYS A CENTRAL ROLE IN FIBROSIS-ASSOCIATED HEPATOCARCINOGENESIS

Author

Carmen Berasain, Maite G. Fernandez-Barrena, Javier Prieto, Raquel Urtasun, Matías A. Avila, Maria U. Latasa, M.R. Elizalde, Iker Uriarte, and Oihane Garcia-Irigoyen

Subjects
endocrine system, Hepatology, business.industry, FGF15, medicine.disease, Chronic liver disease, medicine.disease_cause, Haematopoiesis, Liver disease, Fibrosis, Apoptosis, medicine, Cancer research, Clinical significance, business, Carcinogenesis, hormones, hormone substitutes, and hormone antagonists
Abstract

marrow-derived cells and analyzed the expression of NEMO and pJNK in human diseased-livers. Results: Deletion of Jnk1 significantly aggravated the progression of liver disease, exacerbating apoptosis, compensatory proliferation and carcinogenesis in NEMODhepa mice. Jnk2−/−/NEMODhepa showed increased RIP-1 and RIP-3 expression and hepatic inflammation. Jnk1 in hematopoietic cells rather than hepatocytes had an impact on the progression of chronic liver disease in NEMODhepa livers. These findings are of clinical relevance since down-regulation of NEMO expression was observed in hepatocytes of patients with advanced liver disease. Conclusions: While Jnk1 mediates protective effects in NEMODhepa mice, hematopoietic cells-derived Jnk1 rather than hepatocytes is a crucial driver of hepatic injury. Jnk2 function seems to be independent of Jnk1. These results elucidate the complex function of Jnk in chronic inflammatory liver disease.

Published
2014

9. P62 MMP10 EXPRESSION PROTECTS FROM ACUTE LIVER INJURY BUT CONTRIBUTES TO HEPATOCELLULAR CARCINOMA PROGRESSION

Author

Maria U. Latasa, Raquel Urtasun, Iker Uriarte, Oihane Garcia-Irigoyen, Simone Carotti, Javier Prieto, J.A. Rodriguez, Josune Orbe, J.A. Paramo, Umberto Vespasiani-Gentilucci, Carmen Berasain, M.R. Elizalde, Sergio Morini, Giuseppe Perrone, and Matías A. Avila

Subjects
Cirrhosis, Hepatology, biology, Integrin Inhibition, MMP10, business.industry, Integrin, medicine.disease, Gentamicin protection assay, Downregulation and upregulation, Hepatocellular carcinoma, biology.protein, Cancer research, medicine, Immunohistochemistry, business
Abstract

Background and Aims: avb6 integrin is markedly upregulated in liver fibrosis and human cholangiocarcinoma (CC), and its genetic and pharmaceutical inhibition revealed potent antifibrotic activity in experimental liver fibrosis. Whether avb6 integrin inhibition may interfere with cholangiocarcinogenesis is unknown. Methods: To induce experimental CC, male Sprague-Dawley rats were treated with thioacetamide (TAA) for 22 weeks, followed by specific non-peptidic avb6 integrin inhibitor EMD527040 at 60mg/kg/day i.p. after 9 weeks of TAA. Besides mortality and tumor incidence, expression of avb6 integrin was evaluated by immunohistochemistry and RT-PCR. In vitro, 3D culture cell invasion assay was used to evaluate cholangiocarcinoma TFK-1 cells spheroid formation and invasive capacities. Human liver specimens of patients with cirrhosis, cholangiocarcinoma and normal liver tissues were analyzed by EMT RT ProfilerTM PCR Array (Qiagen). Results: TAA administration in rats induced CC in 80% of animals with no mortality, and an upregulation of avb6 integrin by 15-fold. Treatment with EMD527040 reduced the incidence of CC by 50%, and caused a significant down-regulation of avb6 mRNA expression. In vitro, 10mM EMD527040 completely prevented spheroid formation of cholangiocarcinoma cells TFK-1 in 3D system cultivation, whereas no matrix invasion with this cell type was observed. Microarrays in human CC samples detected a significant upregulation of 4 genes related to EMT: COL1A2, COL3A1, KRT19 and VCAN (p < 0.05), while there was a significant 5-fold downregulation of the EGFR, ESR1, F11R, IL1RN, NUDT13, PPPDE2 and WNT11 genes. Conclusions: Pharmaceutical targeting of avb6 integrin reduces tumor burden in an experimental model of CC, possibly by inhibiting tumor dissemination.

Published
2014

10. 1134 AAV MEDIATED LIVER GENE THERAPY PROVIDES PROLONGED ENZYMATIC CORRECTION AND PROTECTS AGAINST INDUCED MOTOR NEUROPATHY IN ACUTE INTERMITTENT PORPHYRIA MICE

Author

Itsaso Mauleón, Manuel Alegre, A. Fontanellas, Javier Prieto, R. Enríquez de Salamanca, Harald Petry, Carmen Unzu, Stuart G. Beattie, Maria Sol Rodriguez-Pena, Gloria González-Aseguinolaza, Ana Sampedro, Ignacio Melero, Ruben Hernandez-Alcoceba, Julio Artieda, E.J. Timmermans, and Jaap Twisk

Subjects
chemistry.chemical_classification, medicine.medical_specialty, Hepatology, business.industry, Genetic enhancement, medicine.disease, Enzyme, Endocrinology, chemistry, Internal medicine, medicine, business, Motor neuropathy, Acute intermittent porphyria
Published
2010

11. 37 Gene therapy of chronic hepatitis B infection using a high-capacity adenovirus expressing interleukin 12 under the control of a liver specific mifepristone-inducible promoter

Author

Stefan Kochanek, Javier Prieto, Laura Ochoa, Africa Vales, Astrid Pañeda, Gloria González-Aseguinolaza, Cristina Olagüe, and Julien Crettaz

Subjects
Genetically modified mouse, Hepatitis B virus, Cirrhosis, Hepatology, Hepatitis B virus DNA polymerase, viruses, Genetic enhancement, Woodchuck hepatitis virus, virus diseases, Biology, medicine.disease, medicine.disease_cause, biology.organism_classification, Virology, digestive system diseases, Immunology, Interleukin 12, medicine, Liver cancer
Abstract

Three hundred fifty millions people are estimated to be infected by the hepatitis B virus (HBV). Eighty-seven millions of them would develop HBV-related liver cancer or cirrhosis. In this study we developed a high-capacity adenovirus (HC-Ad), characterized by its low toxicity and long-term expression, encoding for the murine interleukin 12 (mIL12) directed by a liver-specific promoter and inducible by the administration of mifepristone (HC-RU-mIL12). We assayed its antiviral effect using two animal models of chronic HBV infection: transgenic mice for the HBV genome and woodchucks chronically infected by the woodchuck hepatitis virus (WHV).

Published
2006

13. 342 LIVER INJURY AND DEVELOPMENT OF SERUM ANTIMITOCHONDRIAL AUTOANTIBODIES IN AE2A,B-DEFICIENT MICE ARE ASSOCIATED WITH LOW LEVELS OF GLUTATHIONE AND INCREASED APOPTOSIS

Author

Sarai Sarvide, Javier Prieto, A. Ferrer, January T. Salas, Jesus M. Banales, Ainhoa Portu, R.P.J. Oude Elferink, and Juan F. Medina

Subjects
Liver injury, chemistry.chemical_compound, Hepatology, chemistry, Apoptosis, business.industry, Immunology, Autoantibody, medicine, Deficient mouse, Glutathione, medicine.disease, business
Published
2012

14. 1028 INCIDENCE AND RISK FACTORS OF RADIOEMBOLIZATION (RE)-INDUCED LIVER DISEASE: RESULTS OF GLOBAL THERAPEUTIC STRATEGY AIMING TO PREVENTION

Author

Alberto Benito, Macarena Rodriguez, Mercedes Iñarrairaegui, Javier Prieto, Bruno Sangro, Jorge Quiroga, J.I. Bilbao, Delia D'Avola, Ignacio Herrero, and B. Gil-Alzugaray

Subjects
Oncology, medicine.medical_specialty, Liver disease, Hepatology, business.industry, Internal medicine, Incidence (epidemiology), medicine, business, medicine.disease, Surgery, Therapeutic strategy
Published
2012

15. 66 CONTROL OF BILE ACIDS LEVELS BY FGF15 IS ESSENTIAL FOR NORMAL LIVER REGENERATION AFTER PARTIAL HEPATECTOMY

Author

Carmen Berasain, Iker Uriarte, Javier Prieto, C.M. Rodriguez-Ortigosa, Maria J. Monte, Jose J.G. Marin, Matías A. Avila, M.G. Fernández de Barrena, and Eva Vicente

Subjects
Hepatology, Chemistry, FGF15, Liver cell, Inflammation, Compartment (chemistry), medicine.disease, Liver regeneration, medicine.anatomical_structure, Fibrosis, Hepatocyte, medicine, Cancer research, medicine.symptom, Progenitor cell
Abstract

F4/80, CD4) in casp8DMx mice. This finally resulted in a stronger fibrosis progression of the underlying sclerosing cholangitis induced by DDC in casp8DMx mice, as evidenced by an enhanced expression of collagen and a-SMA. Conclusion: Caspase8 has a distinct impact on individual liver cell types.While hepatocyte specific knockout provided protection from liver damage an ubiquitous deletion of caspase8 triggered more injury and inflammation. This was finally related to a significantly stronger activation of the liver progenitor cell compartment and more tissue remodelling.

Published
2012

16. 804 MODULATION OF REGULATORY T CELLS ACTIVITY IN COMBINATION WITH IL-12 INDUCES A REBOUND EFFECT INCREASING THE TOLEROGENIC LIVER ENVIRONMENT IN CHRONIC VIRAL HEPATITIS

Author

Javier Prieto, J. Dotor, L. Suárez, Itziar Otano, Cristina Olagüe, M. A González, Gloria González-Aseguinolaza, Stephan Menne, R. Hernández, and Alberto Benito

Subjects
Hepatology, business.industry, Immunology, Interleukin 12, medicine, Rebound effect, Viral hepatitis, medicine.disease, business, Virology
Published
2012

18. 353 INSULIN-LIKE GROWTH FACTOR I ENHANCES BILE-DUCT PROLIFERATION AND FIBROSIS IN ABCB4−/− MICE

Author

Piter J. Bosma, Javier Prieto, S. Arcelus, R.P.J. Oude Elferink, C.M. Rodriguez-Ortigosa, Aleksandar Sokolović, N. Juanarena, and L. ten Bloemendaal

Subjects
Insulin-like growth factor, medicine.medical_specialty, Endocrinology, Hepatology, Fibrosis, Chemistry, medicine.medical_treatment, Internal medicine, medicine, ABCB4, medicine.disease, Bile duct proliferation
Published
2012

19. 273 PROPERTIES AND LIMITATIONS OF MONOCYTES AND CANCER CELLS AS CARRIERS FOR REPLICATION-COMPETENT ADENOVIRAL VECTORS IN LIVER METASTASES OF PANCREATIC CANCER

Author

Sergia Bortolanza, Ruben Hernandez-Alcoceba, Eva Garcia-Aragoncillo, Javier Prieto, Raquel Casado, and Maria Bunuales

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Pancreatic cancer, Replication (statistics), Cancer cell, Medicine, CA19-9, business, medicine.disease
Published
2012

20. 531 IGF-I GENE TRANSFER TO CIRRHOTIC LIVER INDUCES CIRRHOSIS REVERSION IN RATS

Author

J.L. Romero-Trevejo, Javier Prieto, L. Sobrevals, Mónica Enguita, C. Rodriguez, and Puri Fortes

Subjects
medicine.medical_specialty, Cirrhotic liver, Cirrhosis, Endocrinology, Hepatology, business.industry, Internal medicine, Reversion, Medicine, Gene transfer, business, medicine.disease
Published
2010

22. 543 EVALUATION OF SEMLIKI FOREST VIRUS (SFV) VECTORS EXPRESSING IL-12 FOR TREATMENT OF HEPADNAVIRUS-INDUCED HEPATOCELLULAR CARCINOMA (HCC) IN WOODCHUCKS

Author

Julien Crettaz, Bud C. Tennant, N.L. Dykes, S.D. Butler, M. Ruiz-Guillen, Christine A. Bellezza, Gloria González-Aseguinolaza, Javier Prieto, Cristian Smerdou, J.R. Rodriguez-Madoz, I.A. Tochkov, Itziar Otano, Jose I. Quetglas, Katherine H. Liu, and Stephan Menne

Subjects
Hepatology, biology, Hepatocellular carcinoma, Interleukin 12, medicine, Hepadnavirus, Semliki Forest virus, biology.organism_classification, medicine.disease, Virology
Published
2009

23. 612 THE EXTRA DOMAIN A FROM FIBRONECTIN (EDA) IMPROVES IMMUNOGENICITY OF NS3 PROTEIN IN A SEMLIKI FOREST VIRUS (SFV)-BASED VACCINE AGAINST HEPATITIS C

Author

Javier Prieto, Francisco Borrás-Cuesta, Marta Martínez, Cristina Mansilla, E. Casales, Juan José Lasarte, Cristian Smerdou, N. Casares, and Pablo Sarobe

Subjects
Fibronectin, NS3, Hepatology, biology, Immunogenicity, medicine, biology.protein, Hepatitis C, medicine.disease, Semliki Forest virus, biology.organism_classification, Virology, Domain (software engineering)
Published
2008

27. 141 Results of liver transplantation in patients with hepatocellular carcinoma. Milan versus expanded criteria

Author

Bruno Sangro, J.I. Herrero, Javier Prieto, Mercedes Iñarrairaegui, R. Armendariz, Jorge Quiroga, Fernando Pardo, and Fernando Rotellar

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Internal medicine, Hepatocellular carcinoma, medicine, In patient, Liver transplantation, business, medicine.disease, Gastroenterology
Published
2006

28. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial (final report Maag Lever Darm Stichting projectno. WS 00???78 (WS 97/87))

Author

Jan Frystyk, Allan Flyvbjerg, R.J. de Knegt, Bruno Sangro, M Payeras, Plm Jansen, Carl Yoshizawa, Javier Prieto, J.I. Herrero, Bruce F. Scharschmidt, Inma Castilla-Cortázar, Jorge Quiroga, and M. Conchillo

Subjects
medicine.medical_specialty, Lever, Cirrhosis, business.product_category, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, Albumin, medicine.disease, Surgery, Clinical trial, Insulin-like growth factor, Endocrinology, Internal medicine, Medicine, business
Published
2006

30. 180 Results of a randomized double-blind, controlled pilot study of the administration of insulin-like growth factor-I (IGF-I) in patients with liver cirrhosis

Author

J.I. Herrero, Javier Prieto, Bruno Sangro, Jorge Quiroga, P.M.L. Jansen, C. Toshizawa, M. Conchillo, Bruce F. Scharschmidt, R.J. de Knegt, Inma Castilla-Cortázar, and M Payeras

Subjects
Double blind, medicine.medical_specialty, Insulin-like growth factor, Endocrinology, Cirrhosis, Hepatology, business.industry, medicine.medical_treatment, Internal medicine, medicine, In patient, business, medicine.disease
Published
2004

33. A phase I clinical trial of intratumoral injection of adenovirus encoding interleukin-12 in patients with hepatocellular carcinoma and other advanced gastrointestinal tumors

Author

Pablo Sarobe, Belén Sádaba, J. Pueyo, Jorge Quiroga, J. Sola, Maite Herraiz, Bruno Sangro, Alberto Benito, Javier Larrache, J.I. Herrero, Juan Carlos Ruiz, Guillermo Mazzolini, Javier Prieto, Jose Carlos Subtil, and I. MeleroC Qian

Subjects
Oncology, medicine.medical_specialty, Gastrointestinal tumors, Hepatology, business.industry, Internal medicine, Hepatocellular carcinoma, Interleukin 12, medicine, Phases of clinical research, In patient, business, medicine.disease
Published
2003

34. Description of a novel MDR3 gene mutation causing juvenil cholelithiasis, cholelithiasis of pregnancy and adulthood biliary cirrhosis. A family study

Author

J.F. Lucena, J. Sola, Javier Prieto, Bruno Sangro, N. zabalegui, Juan F. Medina, J. Garcia-Foncillas, Maite Herraiz, J.I. Herrero, and Jorge Quiroga

Subjects
Pregnancy, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Biliary cirrhosis, medicine, Gene mutation, medicine.disease, business, Gastroenterology
Published
2003

36. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin-12 (IL-12)

Author

Maider Zabala, Guillermo Mazzolini, Bruno Sangro, G. Genove, Iñigo Narvaiza, Javier Prieto, Miguel Barajas, Cheng Qian, Roberto Bilbao, Volker Schmitz, and Ignacio Melero

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Genetic enhancement, Hepatocellular carcinoma, medicine, Interleukin 12, Cancer research, medicine.disease, business
Published
2001

39. Genetic instability and mismatch repair genes in liver biopsies from patients with advanced liver cirrhosis and from patients with hepatocellular carcinoma developed in previous cirrhosis

Author

J.I. Riezu, J. Garcia-Foncillas, J.I. Herrero, Javier Prieto, and María-Pilar Civeira

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, General surgery, Internal medicine, Hepatocellular carcinoma, medicine, DNA mismatch repair, medicine.disease, business, Gastroenterology
Published
1998

Catalog

Books, media, physical & digital resources
See catalog results